SBIR/STTR Research Award

GENE DIVERSIFICATION BY DIRECTED RETROTRANSPOSITION

Award identifier 160ecf63cc52a7e691fed706b076f8ca3e2acc345474da3d91c88425979db05cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NEUGENESIS CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Gene-products of recombinant origin have substantial commercial value for pharmaceutical and technical uses. Directed evolution approaches to generate new or improved products have successfully been applied in instances where structure-function data for target molecules are limited. Current approaches use in vitro techniques to generate diversity. These methods have a number of shortcomings due to expense and difficulty in creation of large molecular diversity libraries containing new variants. The use of a concerted in vivo process that generates large libraries of cells producing variants of the starting molecule, would result in considerable cost and effort savings. The fungus Neurospora crassa has the ability to correctly express, fold, modify and secrete active eukaryotic proteins, and the ability to "shuffle" DNA sequences in vivo by high-frequency meiotic gene conversion. The addition of a method to induce targeted mutations into an expressed heterologous gene would allow rapid screening of new variants, with no additional molecular manipulations. This proposal investigates the potential to use directed retrotransposition to introduce mutation into heterologous sequences in this fungus. Experiments to demonstrate controlled transduction of transposon-reporter chimeras between genetically marked nuclei will be performed. The long term outcome of this proposal is to generate molecular diversity in target genes, for screening of new activities and products. PROPOSED COMMERCIAL APPLICATION: This proposal tests a new method for in vivo diversification of genes by retrotransposition. This error-prone process may then be used to generate simple and robust molecular diversity libraries for screening of new variants of commercially valuable gene-products. Success will lead to a novel alternative method for directed evolution of new or improved products, allowing entry into markets for new pharmaceutical, industrial and agricultural products.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.